ClinicalTrials.gg
CompletedNCT01650519Updated Jun 23, 2016Results posted

A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery

A Phase 4 interventional study of IV ibuprofen and IV ketorolac in Arthroscopic Knee Surgery, sponsored by Cumberland Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-23.

Sponsored by Cumberland Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The intent of this study is to assess the analgesic efficacy of IV ibuprofen when administered at induction of anesthesia. Results from this pilot study will be used to design and determine the appropriate statistical power for a larger, multi-center randomized study.

Read the detailed description

Non-steroidal anti-inflammatory drugs(NSAIDs) are an effective adjunct to opioid analgesia for moderate-severe pain, with improvement in the quality of pain relief and consistent evidence of opioid dose sparing. NSAIDs alone could provide effective analgesia post-surgery when mild-moderate pain is expected. There is also evidence that the use of NSAIDs, by avoiding or decreasing the need for opioids, can lead to a reduction in the incidence of adverse events which are commonly attributed to, or exacerbated by, opioids.

The intent of this study is to assess the analgesic efficacy of IV ibuprofen when administered at induction of anesthesia. Results from this pilot study will be used to design and determine the appropriate statistical power for a larger, multi-center randomized study.

02

Conditions studied

  • Arthroscopic Knee Surgery

Keywords

  • knee surgery, arthroscopy; orthopaedic, orthopedic surgery
03

In context

Lead sponsor

Cumberland Pharmaceuticals is the lead sponsor of 49 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for knee arthroscopy

Exclusion criteria

Exclusion Criteria:

  • Inadequate intravenous (IV) access.
  • History of allergy or to any component of ibuprofen or other NSAIDs, aspirin (or aspirin related products), opioids or cyclooxygenase-2(COX-2) inhibitors.
  • Less than 18 years of age.
  • Use of analgesics less than 8 hours prior to surgery.
  • Patients with active, anemia.
  • History or evidence of asthma or heart failure.
  • Pregnant.
  • Recent history of chronic non-steroidal anti-inflammatory drug (NSAID) or opioid use.
  • Inability to understand the requirements of the study, be willing to provide written (as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]), and agree to abide by the study restrictions and to return for the required assessments.
  • Refusal to provide written authorization for use and disclosure of protected health information.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    IV ibuprofen

    Intravenous ibuprofen (800 mg) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 (Ibuprofen arm) and a corresponding volume of normal saline (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure

    Drug: IV ibuprofen

  • Active comparator
    IV ketorolac

    A corresponding volume of normal saline (Ibuprofen arm) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 and 30 mg ketorolac for patients \< 65 years of age (15 mg ketorolac for patients \> 65 years of age) (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure

    Drug: IV ketorolac

Interventions

  • 800 mg intravenous ibuprofen administered intravenously over 10 minutes.

    Also known as: Caldolor

  • 30 mg ketorolac for patients \< 65 years of age (15 mg ketorolac for patients \> 65 years of age) administered intravenously over no less than 15 seconds

    Also known as: Toradol

06

What researchers measure

Primary outcomes

  1. Efficacy of IV Ibuprofen for Post-op Pain.

    Measurement of the efficacy of IV ibuprofen for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS) upon first possible assessment following surgery. The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between o and 100.

    Time frame: first possible assessment following surgery

Secondary outcomes

  1. Measurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Amount of Rescue Medication in the Postoperative Period Through Discharge

    Measurement of the amount of rescue medication in the postoperative period.

    Time frame: 24 hours

  2. Time to Discharge.

    Measurement of the time to discharge in the postoperative period.

    Time frame: 24 hours

  3. Patient Satisfaction.

    Measurement of patient satisfaction post-procedure. During the post-treatment period, subjects were asked to complete a satisfaction questionnaire (Quality of Recovery - 40 or QoR-40) defining their quality of recovery at 24 hours following surgery. The QoR - 40 is a 40-item questionnaire that provides a global score and subscores across five dimensions of quality of recovery: emotions (minimum score = 6, maximum score = 30), physical comfort (minimum score = 8, maximum score = 40), patient support (minimum score = 7, maximum score = 35), physical independence (minimum score = 5, maximum score = 25), and pain (minimum score = 7, maximum score = 35). Higher subscores represent a better outcome. Subscores are added to create a Global QoR-40 score. Global scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery).

    Time frame: 24 hours

  4. Incidence of Serious Adverse Events (SAEs).

    Measurement of the incidence of serious adverse events.

    Time frame: 24 hours

  5. Measurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Pain Intensity as Assess by Patient Pain Intensity (VAS) in the Post-surgical Period, Through 24 Hours

    Measurement of the efficacy of IV ibuprofen for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS) in the post-surgical period through 24 hours post-procedure. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. Subject's were contacted at 24 hour post-discharge during a follow-up phone contact and asked to completed the VAS at Rest and VAS with Movement and return both completed VAS assessments via the envelope provided. The analysis was performed on the VAS assessments returned to the study site.

    Time frame: 24 Hours

  6. Measurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Amount of Time to Rescue Medication in the Postoperative Period Through Discharge

    Measurement of the amount of time to rescue medication in the postoperative period.

    Time frame: 24 hours

07

Results

Posted Jul 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneIV IbuprofenIV Ketorolac
Started2031
Completed1931
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryEfficacy of IV Ibuprofen for Post-op Pain.

Measurement of the efficacy of IV ibuprofen for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS) upon first possible assessment following surgery. The VAS is a continuous scale compromised of a horizontal line, one hundred millimeters in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between o and 100.

Time frame:
first possible assessment following surgery
Reported as:
Mean · units on a scale
Efficacy of IV Ibuprofen for Post-op Pain.
units on a scaleIV IbuprofenIV Ketorolac
VAS at Rest (mm)8 ± 6.634 ± 25.0
VAS with Movement (mm)19 ± 17.441 ± 25.8
SecondaryMeasurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Amount of Rescue Medication in the Postoperative Period Through Discharge

Measurement of the amount of rescue medication in the postoperative period.

Time frame:
24 hours
Reported as:
Mean · milligrams
Measurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Amount of Rescue Medication in the Postoperative Period Through Discharge
milligramsIV IbuprofenIV Ketorolac
Narcotic5.4 ± 6.0220.4 ± 15.87
Acetaminophen162.5 ± 229.81325 ± 269.90
SecondaryTime to Discharge.

Measurement of the time to discharge in the postoperative period.

Time frame:
24 hours
Reported as:
Mean · Hours
Time to Discharge.
HoursIV IbuprofenIV Ketorolac
Time to Discharge.1.8 ± 0.121.8 ± 0.08
SecondaryPatient Satisfaction.

Measurement of patient satisfaction post-procedure. During the post-treatment period, subjects were asked to complete a satisfaction questionnaire (Quality of Recovery - 40 or QoR-40) defining their quality of recovery at 24 hours following surgery. The QoR - 40 is a 40-item questionnaire that provides a global score and subscores across five dimensions of quality of recovery: emotions (minimum score = 6, maximum score = 30), physical comfort (minimum score = 8, maximum score = 40), patient support (minimum score = 7, maximum score = 35), physical independence (minimum score = 5, maximum score = 25), and pain (minimum score = 7, maximum score = 35). Higher subscores represent a better outcome. Subscores are added to create a Global QoR-40 score. Global scores range from 40 (extremely poor quality of recovery) to 200 (excellent quality of recovery).

Time frame:
24 hours
Reported as:
Mean · units on a scale
Patient Satisfaction.
units on a scaleIV IbuprofenIV Ketorolac
Emotions20.2 ± 2.3520.7 ± 2.25
Physical Comfort28.3 ± 4.3926.9 ± 2.98
Patient Support30.5 ± 1.2029.0 ± 3.93
Physical Independence22.2 ± 2.5521.3 ± 3.32
Pain9.5 ± 3.4510.9 ± 3.34
SecondaryIncidence of Serious Adverse Events (SAEs).

Measurement of the incidence of serious adverse events.

Time frame:
24 hours
Reported as:
Number · Number of Events
Incidence of Serious Adverse Events (SAEs).
Number of EventsIV IbuprofenIV Ketorolac
Incidence of Serious Adverse Events (SAEs).00
SecondaryMeasurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Pain Intensity as Assess by Patient Pain Intensity (VAS) in the Post-surgical Period, Through 24 Hours

Measurement of the efficacy of IV ibuprofen for the treatment of postoperative pain as measured by patient pain intensity (Visual Analog Scale, VAS) in the post-surgical period through 24 hours post-procedure. The VAS is a continuous scale made up of a horizontal line, 100 mm in length, anchored by 2 verbal descriptors (No Pain, Worst Possible Pain). The VAS is self-completed by the respondent. The subject is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance, in mm, on the 100 mm line between the "No Pain" anchor and the subject's mark. The score would be between 0 and 100. Subject's were contacted at 24 hour post-discharge during a follow-up phone contact and asked to completed the VAS at Rest and VAS with Movement and return both completed VAS assessments via the envelope provided. The analysis was performed on the VAS assessments returned to the study site.

Time frame:
24 Hours
Reported as:
Mean · units on a scale
Measurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Pain Intensity as Assess by Patient Pain Intensity (VAS) in the Post-surgical Period, Through 24 Hours
units on a scaleIV IbuprofenIV Ketorolac
VAS at Rest (mm)4 ± 3.713 ± 10.8
VAS with Movement (mm)12 ± 12.223 ± 16.5
SecondaryMeasurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Amount of Time to Rescue Medication in the Postoperative Period Through Discharge

Measurement of the amount of time to rescue medication in the postoperative period.

Time frame:
24 hours
Reported as:
Mean · Hours
Measurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Amount of Time to Rescue Medication in the Postoperative Period Through Discharge
HoursIV IbuprofenIV Ketorolac
Measurement of the Efficacy of IV Ibuprofen for the Treatment of Postoperative Pain as Measured by the Amount of Time to Rescue Medication in the Postoperative Period Through Discharge1.7 ± 0.191 ± 0.11

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Ibuprofen—0/20 (0%)0/20 (0%)
IV Ketorolac—0/31 (0%)0/31 (0%)

Baseline characteristics

The Intent-to-treat population consists of all patients who received at least a partial dose of study medication.

Age, Customized
Age, Customized(years)IV IbuprofenIV KetorolacTotal
Subject greater than or equal to 18 years of age43 ± 12.645 ± 1344 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)IV IbuprofenIV KetorolacTotal
Female61016
Male142135
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IV IbuprofenIV KetorolacTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American314
White172946
More than one race000
Unknown or Not Reported011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IV IbuprofenIV KetorolacTotal
Hispanic or Latino011
Not Hispanic or Latino203050
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)IV IbuprofenIV KetorolacTotal
United States203151
08

Study locations

1 site
  • The Ohio State University, Wexner Medical Center
    Columbus, Ohio 43210, United States
09

References and documents

Publications

  • Uribe AA, Arbona FL, Flanigan DC, Kaeding CC, Palettas M, Bergese SD. Comparing the Efficacy of IV Ibuprofen and Ketorolac in the Management of Postoperative Pain Following Arthroscopic Knee Surgery. A Randomized Double-Blind Active Comparator Pilot Study. Front Surg. 2018 Oct 3;5:59. doi: 10.3389/fsurg.2018.00059. eCollection 2018. PubMed 30338261 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Dec 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2012
First posted
Jul 26, 2012
Start
Sep 2012
Primary completionActual
Dec 2012
CompletionActual
Jan 2013
Results first posted
Jul 10, 2014
Last update
Jun 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01650519
Responsible party
Sponsor
First posted
Jul 26, 2012
Start date
Sep 2012
Primary completion
Dec 2012
Completion
Jan 2013
Results posted
Jul 10, 2014
Last update
Jun 23, 2016

Study contacts

Fernando L Arbona, MD
principal investigator · The Ohio State University Wexner Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Ketorolac

Start the discussion